6000 W Investment of 60 million yuan
100 + More than 100 cooperative customers
100 W＋ Project value is over million
Zhejiang IPS Pharmaceutical Technology Co., Ltd. is jointly established by Sino Harbour Holdings Group Limited, Irvine Pharmaceutical Services Inc. and Zhejiang University of Technology with a total investment of 60 million yuan. It is a professional third-party drug testing and R&D institution jointly established with Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals with the commitment to providing high-quality drug development services for pharmaceutical companies at home and abroad.
With its high-quality R&D teams and advanced scientific research instruments, and abiding by the standards of cGMP and US FDA, ZJ-IPS strive to build an independent third-party Laboratory that provides pharmaceutical companies with technical services in compliance with China, the United States, the United Kingdom, Japan, the European Pharmacopoeia, American Chemical Society, and American Analytical Chemistry Association (ChP, USP, BP, JP, EP, ACS, AOAC) and customer-specified standards. Upholding the principles of objectiveness, fairness, independence and efficiency, we provide R&D outsourcing services including pharmaceutical analysis and testing, conformity testing, market entry testing, stability testing of APIs and preparations, compatibility studies of pharmaceuticals and packaging materials and quality consistency evaluation of generic drugs.
Sino Harbour Holdings Group Limited (the “Group”), formerly named as Sino Harbour Property Group Limited, is a property developer focused on the second and third tier cities in the P.R.C., with its headquarter in Hong Kong. The Group’s parent company – Pan Hong Holdings Group Limited (SGX:P36) (“Pan Hong Group”) was listed on Singapore Stock Exchange in 2006 and has more than 20 years of property development experience in niche markets in China. Pan Hong Group spun off the Group in 2011 to further expand its business. While the Group is currently principally engaged in the business of property development, it has been exploring and seeking new opportunities to broaden revenue stream and improve profitability. To better reflect the business nature and principal activities of the Group, the Group changed its name to Sino Harbour Holdings Group Limited from Sino Harbour Property Group Limited with effect from 24th August 2015 and began to enter into the pharmaceutical and healthcare industries. Since the change of name, the Group has founded several important subsidiaries including Sino Harbour Bio Technology Limited (“SH BioTech HK”), Jiangxi Sino Harbour Bio Technology Limited, Zhejiang Sino Harbour Bio Technology Limited and Guangxi Guarantee Bio Technology Limited